propargyl isocyanate | 56620-43-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: propargyl isocyanate
• 英文别名: 3-isocyanatoprop-1-yne
• CAS: 56620-43-0
• 化学式: C₄H₃NO
• mdl: MFCD18269640
• 分子量: 81.0739
• InChiKey: SHPPDIBKHYVIKL-UHFFFAOYSA-N

物化性质

• 沸点：
  82.9±23.0 °C(Predicted)
• 密度：
  0.83±0.1 g/cm3(Predicted)
• 溶解度：
  苯（少量溶解）、DMSO

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  propargyl isocyanate 在 水 作用下， 生成 1,3-di(prop-2-yn-1-yl)urea
  参考文献：
  名称：

  Sato, Nippon Kagaku Zasshi, 1956, vol. 77, p. 1411

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1-二苯基-3-(丙-2-炔基)脲 生成 propargyl isocyanate
  参考文献：
  名称：

  [EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG
  [FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX

  摘要：

  提供具有化学式（I）及其药用可接受的盐、水合物或溶剂化合物（I）的其中B、X和Y的定义如本文所述。这些化合物在调节细胞增殖、抑制细胞周期进展和/或促进凋亡的方法中有用，并用于治疗增生性疾病。

  公开号：

  WO2012085501A1

文献信息

• Antitumor imidazo[5,1-d]-1,2,3,5-tetrazines: compounds modified at the 3-position overcome resistance in human glioblastoma cell lines
  作者：David Cousin、Jihong Zhang、Marc G. Hummersone、Charles S. Matthews、Mark Frigerio、Tracey D. Bradshaw、Malcolm F. G. Stevens

  DOI：10.1039/c6md00384b

  日期：——

  Synthetic routes to 3-substituted imidazo[5,1-d]-1,2,3,5-tetrazines structurally related to temozolomide were explored. Interaction of 4-diazoimidazole-5-carboxamide with an isocyanate afforded high product yields when the isocyanate was available in acceptable purity. Alternatively, alkylation of the nor-temozolomide anion afforded high yields of new imidazotetrazines. Several compounds, evaluated

  探索了与替莫唑胺结构相关的3-取代的咪唑并[5,1- d ] -1,2,3,5-四嗪的合成途径。当以可接受的纯度获得异氰酸酯时，4-重氮咪唑-5-羧酰胺与异氰酸酯的相互作用提供了高产物收率。可选地，正-替唑啉酰亚胺阴离子的烷基化提供了高产率的新的咪唑并四嗪。针对含有匹配的MGMT±胶质瘤细胞系的一组化合物评估的几种化合物，无论MGMT的状态如何，均表现出相同的抑制活性。N3-炔丙基-咪唑并四嗪（10m）被优先作为替莫唑胺的替代品，后者能够绕过耐药机制。在Taq聚合酶测定法10m像替莫唑胺及其开环对应物MTIC一样，在三个和五个鸟嘌呤残基簇上的烷基化DNA；在哌啶裂解试验中检测到鸟嘌呤N-7位的共价修饰。化合物10m没有交联DNA，但是通过γ-H2AX检测证明诱导了双链断裂。炔丙基取代的咪唑三嗪（13g）显示出与10m相当的活性，表明新的咪唑四嗪的双环核开环可能是活性所必需的。
• A facile synthesis of unsymmetrical ureas
  作者：Andrey V. Bogolubsky、Sergey V. Ryabukhin、Sergey E. Pipko、Oleg Lukin、Alexander Shivanyuk、Dmytro Mykytenko、Andrey Tolmachev

  DOI：10.1016/j.tet.2011.03.101

  日期：2011.5

  versatile method for the synthesis of unsymmetrical ureas from readily available reagents is reported. In the first step trifluoroethylchloroformate is reacted with a stoichiometric amount of a primary amine to give an intermediate trifluoroethyl carbamate. The addition of a second amine (primary or secondary) to the trifluoroethyl carbamate furnishes corresponding unsymmetrical ureas in 75–85% yield. A

  报道了一种由容易获得的试剂合成不对称脲的简便而通用的方法。在第一步中，使三氟乙基氯甲酸酯与化学计算量的伯胺反应，得到中间体三氟乙基氨基甲酸酯。在氨基甲酸三氟乙酯中添加第二种胺（伯胺或仲胺）可提供相应的不对称脲，产率为75-85％。简单的后处理程序，获得的高收率和分离产物的纯度适用于具有高结构和功能多样性的不对称脲组合库的平行合成。
• [EN] ALIPHATIC PROLINAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE PROLINAMIDE ALIPHATIQUE
  申请人：INCEPTION 4 INC

  公开号：WO2017222917A1

  公开（公告）日：2017-12-28

  This invention is directed to novel aliphatic prolinamide derivatives of Formula I, and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention. The compounds of the invention are inhibitors of HTRAl. Thus, the compounds of the invention are useful in the prevention and treatment of a wide range of diseases mediated (in whole or in part) by HTRAl. The compounds of the invention are also useful for inhibiting HTRAl protease activity in an eye or locus of an arthritis or related condition.

  这项发明涉及一种新型的脂肪族脯氨酰胺衍生物，其化学式为I，并且包括药学上可接受的盐、溶剂化合物、盐的溶剂化合物和其前药，用于预防（例如，延缓或减少发展风险）和治疗（例如，控制、缓解或减缓进展）与眼睛相关的年龄相关性黄斑变性（AMD）及相关眼部疾病。这些疾病包括干性AMD、湿性AMD、地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的退化。本公开的发明还涉及预防、减缓进展和治疗干性AMD、湿性AMD和地理性萎缩、糖尿病视网膜病变、早产儿视网膜病变、多发性脉络膜血管病变以及视网膜或光感受器细胞的方法，包括：给予所述发明化合物的治疗有效量。本发明的化合物是HTRAl的抑制剂。因此，本发明的化合物在预防和治疗一系列（全部或部分）由HTRAl介导的疾病中具有用途。本发明的化合物还可用于抑制眼部或关节炎或相关疾病部位的HTRAl蛋白酶活性。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：UNIV NOTTINGHAM

  公开号：WO2020240199A1

  公开（公告）日：2020-12-03

  The invention provides a product which is a compound of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof: (I) wherein: X is selected from: hydrogen; a methyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl; and an ethyl group which is either unsubstituted or is substituted with from one to five F substituent groups; Y is selected from: hydrogen; a methyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl; and an ethyl group which is either unsubstituted or is substituted with from one to five F substituent groups; RA is hydrogen, or is a C1-2 alkyl group which is optionally substituted, wherein any substituent groups present are independently selected from hydroxyl, halo and NR'2, where each R' is independently selected from hydrogen and methyl.

  该发明提供了一种化合物产品，其化学式为(I)，或其药学上可接受的盐、水合物或溶剂化合物：(I)其中：X选自：氢；一个甲基基团，可选择地被取代，其中任何存在的取代基独立地选自羟基、卤素和NR'2，其中每个R'独立地选自氢和甲基；和一个乙基基团，要么未取代，要么被从一个到五个F取代基团取代；Y选自：氢；一个甲基基团，可选择地被取代，其中任何存在的取代基独立地选自羟基、卤素和NR'2，其中每个R'独立地选自氢和甲基；和一个乙基基团，要么未取代，要么被从一个到五个F取代基团取代；RA为氢，或是一个可选择地被取代的C1-2烷基基团，其中任何存在的取代基独立地选自羟基、卤素和NR'2，其中每个R'独立地选自氢和甲基。
• N-(Propargyl)diazenecarboxamides for ‘click’ conjugation and their 1,3-dipolar cycloadditions with azidoalkylamines in the presence of Cu(II)
  作者：Damijana Urankar、Miha Steinbücher、Jaka Kosjek、Janez Košmrlj

  DOI：10.1016/j.tet.2010.02.042

  日期：2010.4

  Propargyl functionalized diazenes 1 were prepared by two different approaches and were examined as alkyne click components in copper-catalyzed azide–alkyne cycloadditions (CuAAC) with 2-(azidomethyl)pyridine 5a and four α-azido-ω-aminoalkanes C2–C5 (5b–e). Whereas the reactions with azidoalkylamines 5b–e reached completion with copper(II) sulfate without the need of reducing agent typically in no more

  炔丙基官能化的二氮烯1通过两种不同的方法制备，并在铜催化的叠氮化物-炔烃环加成（CuAAC）中与2-（叠氮甲基）吡啶5a和四个α-叠氮基-ω-氨基链烷烃C2-C5（5b – e）。与叠氮基烷基胺5b - e的反应通常用硫酸铜（II）在不需要还原剂的情况下通常在不超过几分钟的时间内完成，而2-（叠氮甲基）吡啶5a需要添加金属铜和更长的反应时间（2 –24小时）。研究了反应性的这种差异，并根据其对CuAAC的碱效应和邻近效应进行了研究。